US6458772B1
(en)
|
1909-10-07 |
2002-10-01 |
Medivir Ab |
Prodrugs
|
GB8725939D0
(en)
*
|
1987-11-05 |
1987-12-09 |
Wellcome Found |
Therapeutic compounds
|
GB8829571D0
(en)
*
|
1988-12-19 |
1989-02-08 |
Wellcome Found |
Antiviral compounds
|
US5677308A
(en)
*
|
1996-12-19 |
1997-10-14 |
Lerner; A. Martin |
Method for alleviating spasmodic torticollis
|
US6399622B1
(en)
|
1997-02-18 |
2002-06-04 |
A. Martin Lerner |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
US5872123A
(en)
|
1997-02-18 |
1999-02-16 |
Lerner; A. Martin |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
US6537997B1
(en)
|
1997-02-18 |
2003-03-25 |
A. Martin Lerner |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
ATE200900T1
(de)
*
|
1997-08-15 |
2001-05-15 |
Medivir Ab |
Analoge nukleoside, wie antivirale einschliesslich inhibitoren der retroviralen reverstranskriptase und der dna polymerase des hepatitis b virus
|
US20020128301A1
(en)
*
|
1998-02-13 |
2002-09-12 |
Medivir AB |
Non-nucleoside reverse transcriptase inhibitors
|
US6444652B1
(en)
|
1998-08-10 |
2002-09-03 |
Novirio Pharmaceuticals Limited |
β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
|
MXPA01001507A
(es)
*
|
1998-08-10 |
2003-09-10 |
Novirio Pharmaceuticals Ltd |
°l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
|
US6107303A
(en)
*
|
1999-03-15 |
2000-08-22 |
Demarco; Charlene C. |
Treatment of Epstein Barr infection
|
US6448256B1
(en)
|
1999-05-24 |
2002-09-10 |
University Of Massachusetts |
Antibiotic prodrugs
|
GB0010446D0
(en)
*
|
2000-04-28 |
2000-06-14 |
Glaxo Wellcome Kk |
Pharmaceutical formulation
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
JP5230052B2
(ja)
*
|
2000-05-26 |
2013-07-10 |
イデニクス(ケイマン)リミテツド |
フラビウイルスおよびペスチウイルス治療のための方法および組成物
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
US6875751B2
(en)
*
|
2000-06-15 |
2005-04-05 |
Idenix Pharmaceuticals, Inc. |
3′-prodrugs of 2′-deoxy-β-L-nucleosides
|
US20030212051A1
(en)
*
|
2001-04-06 |
2003-11-13 |
Polli James E |
Bile acid containing prodrugs with enhanced bioavailabilty
|
EP1436295A4
(en)
*
|
2001-09-07 |
2007-07-11 |
Teva Pharma |
CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
|
EP1435974A4
(en)
*
|
2001-09-28 |
2006-09-06 |
Idenix Cayman Ltd |
METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
|
JP2005511612A
(ja)
*
|
2001-11-05 |
2005-04-28 |
グラクソ グループ リミテッド |
塩酸バラシクロビルの無水結晶形
|
CA2649826A1
(en)
|
2001-11-14 |
2003-05-22 |
Teva Pharmaceutical Industries Ltd. |
Synthesis and purification of valacyclovir
|
BR0214944A
(pt)
*
|
2001-12-14 |
2005-06-07 |
Pharmasset Ltd |
Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais
|
US7211570B2
(en)
*
|
2001-12-20 |
2007-05-01 |
Pharmasset, Inc. |
Treatment of EBV and KHSV infection
|
SE521676C2
(sv)
*
|
2002-01-02 |
2003-11-25 |
Dilafor Ab |
Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
|
KR20040094692A
(ko)
*
|
2002-02-14 |
2004-11-10 |
파마셋, 리미티드 |
변형된 불소화 뉴클레오사이드 유사체
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
US20060147519A1
(en)
*
|
2002-06-24 |
2006-07-06 |
Ashish Gogia |
Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
|
NZ537662A
(en)
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
WO2004002422A2
(en)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
TW200500374A
(en)
|
2002-06-28 |
2005-01-01 |
Idenlx Cayman Ltd |
2' and 3' -nucleoside produrgs for treating flavivridae infections
|
JP5087211B2
(ja)
|
2002-06-28 |
2012-12-05 |
イデニクス(ケイマン)リミテツド |
フラビウィルス感染治療のための2′および3′−ヌクレオシドプロドラッグ
|
TWI244393B
(en)
*
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
US20050043329A1
(en)
*
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
WO2004024095A2
(en)
*
|
2002-09-13 |
2004-03-25 |
Idenix (Cayman) Limited |
ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
|
AU2003277433A1
(en)
*
|
2002-10-16 |
2004-05-04 |
Teva Pharmaceutical Industries Ltd. |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
US20050059684A1
(en)
*
|
2002-10-16 |
2005-03-17 |
Ben-Zion Dolitzky |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
CN1319972C
(zh)
*
|
2002-10-16 |
2007-06-06 |
特瓦制药工业有限公司 |
在盐酸伐昔洛韦结晶中减少残留醇类物质的方法
|
CA2506129C
(en)
|
2002-11-15 |
2015-02-17 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
TWI332507B
(en)
*
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
CA2548608A1
(en)
*
|
2002-12-09 |
2004-06-24 |
Texcontor Etablissement |
Anhydrous crystalline form of valacyclovir hydrochloride
|
CN1742018A
(zh)
*
|
2002-12-10 |
2006-03-01 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒的核苷衍生物
|
AU2003300901A1
(en)
|
2002-12-12 |
2004-06-30 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
NZ540913A
(en)
*
|
2002-12-23 |
2008-02-29 |
Idenix Cayman Ltd |
Process for the production of 3'-nucleoside prodrugs
|
ATE398455T1
(de)
*
|
2003-01-14 |
2008-07-15 |
Gilead Sciences Inc |
Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
|
KR20060008297A
(ko)
*
|
2003-03-20 |
2006-01-26 |
마이크로 바이올로지카 퀴미카 이 파마슈티카 리미티드 |
2'-데옥시-β-L-뉴클레오시드의 제조방법
|
US7595390B2
(en)
*
|
2003-04-28 |
2009-09-29 |
Novartis Ag |
Industrially scalable nucleoside synthesis
|
WO2005003147A2
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
AU2003232719A1
(en)
*
|
2003-05-30 |
2005-01-21 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Novel crystalline forms of valacyclovir hydrochloride
|
EP2014660A3
(en)
|
2003-06-02 |
2009-07-15 |
Teva Pharmaceutical Industries Ltd |
Novel crystalline forms of valacyclovir hydrochloride
|
BRPI0412031A
(pt)
*
|
2003-06-30 |
2006-09-19 |
Idenix Cayman Ltd |
sìntese de beta-l-2'-deóxi-nucleosìdeos
|
US20050025839A1
(en)
*
|
2003-07-28 |
2005-02-03 |
Polli James Edward |
Formulation approach to enhance transporter-mediated drug uptake
|
US20050137141A1
(en)
*
|
2003-10-24 |
2005-06-23 |
John Hilfinger |
Prodrug composition
|
US20070167353A1
(en)
*
|
2003-10-24 |
2007-07-19 |
John Hilfinger |
Prodrug composition
|
US7253175B2
(en)
*
|
2003-11-13 |
2007-08-07 |
Barnet Liberman |
Method for treating athlete's foot
|
CN1980657A
(zh)
|
2004-05-05 |
2007-06-13 |
耶鲁大学 |
新颖的抗病毒赛菊宁黄质类似物
|
AU2005256963A1
(en)
*
|
2004-06-23 |
2006-01-05 |
Centre National De La Recherche Scientifique |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
CA2578750A1
(en)
*
|
2004-09-04 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
|
SI3109244T1
(sl)
|
2004-09-14 |
2019-06-28 |
Gilead Pharmasset Llc |
Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
|
US20060178512A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Cheruthur Govindan |
Method for preparing amino acid esters of nucleoside analogues
|
ATE546451T1
(de)
|
2005-05-25 |
2012-03-15 |
Lilly Co Eli |
Cyclopropancarbonsäureester von acyclovir
|
TWI471145B
(zh)
|
2005-06-13 |
2015-02-01 |
Bristol Myers Squibb & Gilead Sciences Llc |
單一式藥學劑量型
|
TWI375560B
(en)
*
|
2005-06-13 |
2012-11-01 |
Gilead Sciences Inc |
Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
|
EP1746098A1
(en)
*
|
2005-07-21 |
2007-01-24 |
SOLMAG S.p.A. |
Valacyclovir polymorphs and a process for the preparation thereof
|
US20070112193A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Khunt Mayur D |
Valacyclovir process
|
WO2007075876A2
(en)
|
2005-12-23 |
2007-07-05 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
GB0605344D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Pliva Istrazivanje I Razvoj D |
Pharmaceutically acceptable salts and polymorphic forms
|
CN101534848B
(zh)
|
2006-09-19 |
2013-07-17 |
亚洲大学校产学协力团 |
抗动物病毒的抗病毒剂
|
US20080167325A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Bs Praveen Kumar |
Valacyclovir compositions
|
JP2010515747A
(ja)
*
|
2007-01-12 |
2010-05-13 |
ビオマリン プハルマセウトイカル インコーポレイテッド |
テトラヒドロビオプテリンプロドラッグ
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US20080281099A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Mayur Devjibhai Khunt |
Process for purifying valacyclovir hydrochloride and intermediates thereof
|
US20090076039A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched valacyclovir
|
AU2008347005B2
(en)
*
|
2008-01-03 |
2013-10-03 |
Biomarin Pharmaceutical Inc. |
Pterin analog for treating BH4 responsive condition
|
WO2009120358A1
(en)
*
|
2008-03-27 |
2009-10-01 |
Nektar Therapeutics |
Oligomer-nitrogenous base conjugates
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2010075517A2
(en)
*
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Nucleoside analogs
|
SG172363A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
CL2009002207A1
(es)
|
2008-12-23 |
2011-02-18 |
Gilead Pharmasset Llc |
Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
AP3515A
(en)
|
2010-03-31 |
2016-01-11 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
JP6069215B2
(ja)
|
2010-11-30 |
2017-02-01 |
ギリアド ファーマセット エルエルシー |
化合物
|
CN102584825B
(zh)
*
|
2011-01-17 |
2014-04-02 |
四川科伦药物研究有限公司 |
一种合成盐酸伐昔洛韦的方法
|
US20140296520A1
(en)
*
|
2011-11-25 |
2014-10-02 |
Piramal Enterprises Limited |
Process for the preparation of valacyclovir hydrochloride
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US20140100238A1
(en)
|
2012-10-04 |
2014-04-10 |
Ohio State University |
Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
|
US20140213600A1
(en)
*
|
2013-01-29 |
2014-07-31 |
Lily Hsiao |
Medicament for treating peripheral neuropathies
|
TW201429475A
(zh)
*
|
2013-01-29 |
2014-08-01 |
Li-Ly Hsiao |
使用抗病毒藥治療末稍神經病變之疾病
|
ES2900570T3
(es)
|
2013-08-27 |
2022-03-17 |
Gilead Pharmasset Llc |
Formulación de combinación de dos compuestos antivirales
|
CN115745997A
(zh)
*
|
2022-11-30 |
2023-03-07 |
湖北省宏源药业科技股份有限公司 |
一种高纯度伐昔洛韦杂质h制备方法
|